Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$56.27 - $73.77 $1.85 Million - $2.42 Million
32,821 Added 518.83%
39,147 $2.7 Million
Q4 2023

Feb 13, 2024

BUY
$59.06 - $75.72 $1,299 - $1,665
22 Added 0.35%
6,326 $467,000
Q3 2023

Nov 14, 2023

BUY
$65.94 - $99.04 $105,965 - $159,157
1,607 Added 34.21%
6,304 $430,000
Q2 2023

Aug 09, 2023

SELL
$62.68 - $95.05 $47,135 - $71,477
-752 Reduced 13.8%
4,697 $441,000
Q1 2023

May 15, 2023

SELL
$47.19 - $70.77 $49,171 - $73,742
-1,042 Reduced 16.05%
5,449 $369,000
Q4 2022

Feb 14, 2023

BUY
$30.35 - $53.15 $197,001 - $344,996
6,491 New
6,491 $321,000
Q1 2022

May 12, 2022

SELL
$57.56 - $82.54 $471,013 - $675,424
-8,183 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$72.5 - $100.68 $11,527 - $16,008
-159 Reduced 1.91%
8,183 $637,000
Q3 2021

Nov 16, 2021

BUY
$90.24 - $124.05 $521,677 - $717,133
5,781 Added 225.73%
8,342 $796,000
Q2 2021

Aug 13, 2021

BUY
$93.66 - $139.27 $239,863 - $356,670
2,561 New
2,561 $318,000
Q4 2020

Feb 17, 2021

SELL
$99.61 - $142.12 $655,334 - $935,007
-6,579 Closed
0 $0
Q3 2020

Nov 13, 2020

BUY
$72.92 - $102.01 $206,290 - $288,586
2,829 Added 75.44%
6,579 $671,000
Q2 2020

Aug 13, 2020

SELL
$55.75 - $92.75 $99,402 - $165,373
-1,783 Reduced 32.22%
3,750 $326,000
Q1 2020

May 08, 2020

BUY
$37.9 - $104.44 $94,674 - $260,891
2,498 Added 82.31%
5,533 $321,000
Q4 2019

Feb 10, 2020

BUY
$77.66 - $99.74 $235,698 - $302,710
3,035 New
3,035 $277,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Cetera Advisors LLC Portfolio

Follow Cetera Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cetera Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cetera Advisors LLC with notifications on news.